These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 12953938)
1. Regression of cutaneous intravascular lymphoma with rituximab. Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938 [TBL] [Abstract][Full Text] [Related]
2. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Bonnekoh B; Schulz M; Franke I; Gollnick H J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303 [TBL] [Abstract][Full Text] [Related]
3. [Cutaneous B-cell lymphoma treatment with rituximab: two cases]. Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128 [TBL] [Abstract][Full Text] [Related]
4. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581 [TBL] [Abstract][Full Text] [Related]
5. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503 [TBL] [Abstract][Full Text] [Related]
6. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299 [TBL] [Abstract][Full Text] [Related]
7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825 [TBL] [Abstract][Full Text] [Related]
16. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases. Kennedy GA; Blum R; McCormack C; Prince HM Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906 [TBL] [Abstract][Full Text] [Related]
17. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152 [TBL] [Abstract][Full Text] [Related]
18. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647 [TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593 [TBL] [Abstract][Full Text] [Related]
20. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma. Rey J; Wickenhauser S; Ivanov V; Coso D; Gastaut JA; Bouabdallah R J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):210. PubMed ID: 18482321 [No Abstract] [Full Text] [Related] [Next] [New Search]